IT is well established that tumour xenografts, including tumours from patients with primary cancer, can be grown in thymectomized, irradiated mice reconstituted with syngeneic bone marrow cells (T-B+) (Castro, 1972; Franks, Perkins and Holmes, 1973; Cobb and Mitchley, 1974) . In all these studies, a method similar to that of Miller et al. (1963) has been used to produce the T-B+ mice, although the technique proposed by Miller and his colleagues formed the basis for investigations unrelated to tumour growth. Nevertheless, a high degree of positive " takes " has been reported using this method. It has also been observed that some tumours regress immediately after implantation whilst the same tumours, in other T-B+ mice, continue to grow. The reasons for this variation in growth are not entirely clear. However, it is possible that this may be due in part to the fact that, following irradiation of the mice at 900 rad, some 5%/o of viable thymus-dependent (T) lymphocytes are known to survive (Raff and Wortis, 1970) . A further 5 o of T cells are introduced with the syngeneic bone marrow cell inoculum (Doenhoff and Davies, 1971) Female CBA mice from the specific pathogen-free colony at the National Institute for Medical Research, Mill Hill, London, NW7 4RD were used in the study. They were thymectomized at 4 weeks of age and whole body irradiated with a lethal dose (900 rad and 1200 rad) from a 60Co source 2 weeks later. Some mice from each irradiation group were reconstituted with 107 syngeneic bone marrow cells which had been previously incubated with 0 5 ml of ATS for 3 h at 37°C. The remaining mice received an inoculum of 107 untreated syngeneic bone marrow cells. Sixty mice were used in the study.
The anti-thymocyte serum was prepared by the method of Levey and Medawar (1966) . Its efficacy in vivo was tested by the metlhod of Stanbridge and Perkins (1969) . Twvo tumour lines were studied. The HeLa cells used were originally obtained from the Central Public Health Laboratories, Colindale, but were subsequently passaged in the laboratory. They were shown to be free from mycoplasma. Each mouse received 2 x 105 cells in a 0-2 ml inoculum by the subcutaneous route. The remaining mice received pieces of solid tumour at least 9 mm3 from a papillary cell carcinoma of the human bladder on its fourth passage, also by the subcutaneous route. Histology confirmed the presence of a highly anaplastic tumour.
Growth of both implanted tumours was assessed by measuring 2 axes at rightangles using vernier callipers. The product of the axes was designated the surface area of the tumour.
RESULTS AND DISCUSSION
Figures 1 and 2 demonstrate the growth patterns observed from the implanted HeLa and bladder tumours respectively. Figure 1 shows that ATS treatment of the bone marrow cells used to reconsitute the mice irradiated at 900 rad enhanced the growth ofHeLa tumours. This enhancement persisted for more than 50 days after implantation (+ 50). By Day + 63, the tumours implanted in the 900 rad mice showed sustained growth whereas the tumours in the 900 rad + ATS mice had regressed. A similar enhanced growth pattern was observed in the 1200 rad + ATS mice but by Day + 47 there was little difference in size between these tumours and those in the 1200 rad mice. Unfortunately, the 1200 rad + ATS mice died at Day + 50. By Day + 63, the 1200 rad mice showed a rapid growth rate, which was maintained to the end of the study. However, this was always below the growth observed in the 900 rad or 900 rad + ATS groups of mice.
In Fig. 2 Day + 70 the growths observed were exceeded only by the 900 rad + ATS mice. In this study, the 1200 rad + ATS mice died within a few days of implantation of the tumour.
From the results, it is clear that the combination of irradiation and ATS incubated bone marrow cells enhances
subcutaneous growth of tumour xenografts derived from HeLa cell suspensions and solid tumour implants. This suggests that the 500 T cell population introduced with the bone marrow cell inoculum may be the significant factor controlling the inhibition of implanted tumour growth. In this study, it is not clear why the HeLa tumours started to regress in the 900 rad + ATS mice at Day + 63. However, Medawar (1969) has shown that ATS treated mice do not recover full immunological competence until 50 days after the end of ATS treatment. It is therefore possible that the combination of a return to immunological competence and the relatively small tumour load present is responsible for the gradual regression observed. This did not occur in the bladder tumour at 900 rad + ATS because by Day + 63 the surface area of the tumours was 4 times as great as in the mice with the HeLa tumours, thus indicating a well established graft. In the 900 rad mice, growth was slow in both tumour groups. It is suggested this is due to the presence of the small pool of immunologically competent cells introduced with the bone marrow cell inoculum, against which the establishment of tumour growth is achieved.
The comparatively slow growth rates initially obtained at 1200 rad (with or without ATS) may be due to subcutaneous damage following irradiation, thus inhibiting nutrition of the implanted tumours. Even after a recovery period, high irradiation levels do not appear to be superior to the lower levels of irradiation used. The failure to produce surviving 1200 rad + ATS mice in the solid tumour groups is thought to be due to the combined effect of 1200 rad, ATS, and ether anaesthesia. Ether anaesthesia was not required when HeLa cells were injected. In this particular study, there was no observed variation in the inter-mouse survival of tumours.
The combination of 900 rad + bone marrow cells incubated with ATS enhanced growth of implanted tumours and, in the case of solid tumours, sustained enhanced growth in excess of 2200 at Day + 70 when compared with the 900 rad mice. The use of bone marrow incubated with ATS (rather than bone marrow alone) is therefore considered to be a worthwhile addition to the standard technique for growing tumour xenografts.
